OncoMatch/Clinical Trials/NCT07841574
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
Official title: Hepatic Arterial Infusion Chemotherapy Combined With Iparomlimab/Tuvonralimab (QL1706) and Bevacizumab in Patients With Unresectable HER2-Negative Intrahepatic Cholangiocarcinoma:A Prospective Phase II Study
Is NCT07841574 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab for intrahepatic cholangiocarcinoma.
Treatment: hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab — Intrahepatic cholangiocarcinoma (ICC) has an increasing global incidence, and over 70% of patients are diagnosed at unresectable stages with limited survival benefits from standard first-line chemotherapy regimens. Hepatic arterial infusion chemotherapy (HAIC) delivers high-concentration local chemotherapy to liver tumors, while the PD-1/CTLA-4 dual antibody iparomlimab and tuvonralimab (QL1706) combined with bevacizumab can reshape the immunosuppressive tumor microenvironment and exert synergistic anti-tumor effects.The purpose of this study is to evaluate the efficacy and safety of HAIC-FOLFOX plus QL1706 and bevacizumab as first-line therapy for patients with unresectable HER2-negative intrahepatic cholangiocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor therapy for intrahepatic cholangiocarcinoma
No prior anti-tumor treatment for intrahepatic cholangiocarcinoma
Cannot have received: anti-tumor therapy (including interferon) for ICC
Prior anti-tumor therapy (including interferon) for ICC
Lab requirements
Blood counts
Absolute neutrophil count ≥ 2.0 × 10⁹/L; Hemoglobin ≥ 100 g/L; Platelet count ≥ 75 × 10⁹/L; Prothrombin time normal or ≤ 4 sec above ULN; INR ≤ 2.2
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
Total serum bilirubin < 2 × ULN; ALT < 3 × ULN; AST < 3 × ULN; Child-Pugh score ≤ 6 (Child-Pugh A class)
Laboratory test results meet the following criteria (or achievable after short-term medical intervention): ... Child-Pugh score ≤ 6 (Child-Pugh A class).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07841574 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages